3//SEC Filing
Polaris Partners GP VIII, L.L.C. 3
Accession 0000899243-20-019463
CIK 0001807901other
Filed
Jul 15, 8:00 PM ET
Accepted
Jul 16, 8:36 PM ET
Size
17.8 KB
Accession
0000899243-20-019463
Insider Transaction Report
Form 3
Polaris Partners GP VIII, L.L.C.
10% Owner
Holdings
- (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (272,046 underlying) - (indirect: See footnote)
Series A Preferred Stock
→ Common Stock (2,783,892 underlying) - (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (9,736 underlying) - (indirect: See footnote)
Series A Preferred Stock
→ Common Stock (99,637 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock is convertible into Common Stock on a 5.0994-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Managing Members may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]The reportable securities are owned directly by Polaris Entrepreneurs' Fund VIII, L.P. ("PEF VIII"). PPGP VIII is the general partner of PEF VIII. Each of the Managing Members may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F4]The Series B Preferred Stock is convertible into Common Stock on a 5.0994-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Issuer
Pandion Therapeutics, Inc.
CIK 0001807901
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001818137
Filing Metadata
- Form type
- 3
- Filed
- Jul 15, 8:00 PM ET
- Accepted
- Jul 16, 8:36 PM ET
- Size
- 17.8 KB